Compare Moderna, Inc. (MRNA) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs TeraWulf Inc — how do they compare? Moderna, Inc. trades at $137.54 (market cap $56.02B), while TeraWulf Inc trades at $17.03 (market cap $8.91B). The key difference: Moderna, Inc. is far larger — about 6.3× TeraWulf Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, TeraWulf Inc nearer its low. Which is the better fit depends on your goals.
| MRNA | WULF | |
|---|---|---|
Market Cap | $56.02B | $8.91B |
Sector | Health | Technology |
52-Week High | $174.38 | $28.98 |
52-Week Low | $22.36 | $10.49 |
Enterprise Value | $52.17B | $11.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
WULF trades at $17.86, up 8.18% today, amid a bullish technical signal despite mixed moving averages. The company reported a net loss of $661.42M in 2025 with a negative net margin of -1,179.94%, though revenue was $168.46M. Recent news highlights its pivot to AI data centers, including a Kentucky power agreement approval (GlobeNewsWire, 2026-08-24).
Analyst consensus is strongly bullish with a $35.94 price target, but high valuation ratios and persistent losses pose risks. Investment opportunity hinges on successful execution of AI infrastructure expansion, while risks include cash burn and competitive pressures in the data center space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
